KCT0009102尚未招募Unknown
A single-center clinical study to evaluate the safety and efficacy of autologous bone marrow-derived DCs(CellgramDC-WT1) and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed first-line or more standard chemotherapy
Soon Chun Hyang University Hospital Seoul0 个研究点目标入组 10 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 79(Year)（—）
- 性别
- All
入选标准
- •(1) 19 or older and under 80
- •(2) Patients diagnosed histologically with pancreatic cancer, recurrent, metastatic
- •(3) Patients confirmed to have progressed the disease in accordance with RECIST v1.1 after standard chemotherapy of primary or higher
- •(4) Patients who meet full-body performance status ECOG 0-2
- •(5) Patients with at least one measurable lesion according to RECIST v1.1
- •(6) Patients who have not received surgery, radiotherapy, or immunotherapy within the past 4 weeks and have recovered from side effects (However, tissue collection procedures that do not affect the condition of the subject are allowed at the discretion of the researcher)
- •(7) Patients who agreed to use medically recognized contraception during the clinical study participation period
- •(8) Patients who can conduct clinical research in accordance with the clinical research plan
- •(9) Patients who have agreed in writing to participate in this clinical study voluntarily
排除标准
- •(1) Patients with malignant tumors other than non-melanoma skin cancer in the last 3 years
- •(2) Patients who have previously received anti-tumor immunotherapy (such as anti-PD1, anti-PDL-1 or CTLA4 inhibitor) or participated in clinical studies related to immunotherapy or cell therapy
- •(3) Patients with active autoimmune diseases requiring systemic immunosuppression therapy
- •(4) a patient with a history of organ or hematopoietic stem cell transplantation
- •(5) Patients with acute or chronic infections requiring systemic treatment
- •(6) a patient known to be positive for human immunodeficiency virus (HIV) infection/serum
- •(7) Patients with active hepatitis A, B or C
- •(8) an untreated syphilis patient
- •(9) Patients who received a live virus vaccine (e.g. measles, mumps, rubella, chickenpox, yellow fever, rabies, BCG, oral typhoid vaccine, Flu-Mist, etc.) within 30 days
- •(10) Pregnant or breastfeeding patient
- •(11) In addition, if the Tester deems that he/she is not suitable for clinical research
研究者
相似试验
进行中（未招募）
2 期
A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapyCancer - MyelomaMultiple MyelomaACTRN12615000934549Australiasian Leukaemia and Lymphoma Group50
进行中（未招募）
不适用
Alisporivir con pegIFN / RBV in pazienti con epatite C cronica con precedente fallimento terapeutico all'inibitore della proteasiEUCTR2011-004653-31-ITOVARTIS FARMA173
进行中（未招募）
不适用
Alisporivir with pegIFN/RBV in protease inhibitor (PI) treatment failure patients with chronic hepatitis CEUCTR2011-004653-31-DEovartis Pharma Services AG173
进行中（未招募）
不适用
Alisporivir with pegIFN/RBV in protease inhibitor (PI) treatment failure patients with chronic hepatitis CChronic hepatitis C genotype 1 protease inhibitor (PI) treatment failureMedDRA version: 14.1Level: LLTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2011-004653-31-ESovartis Farmacéutica S.A173
进行中（未招募）
不适用
Alisporivir with pegIFN/RBV in protease inhibitor (PI) treatment failure patients with chronic hepatitis CEUCTR2011-004653-31-GBovartis Pharma Services AG173